Search
William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall...
7 days ago
William Blair biotech analyst Andy Hsieh takes stock of the obesity space after attending the 2025 American Diabetes Association's (ADA's) 85th Scientific Sessions in Chicago
He discusses data presented at #ADA25 including Eli Lillys Orforglipron and Bimagrumab, Novo Nordisk's CagriSema, and Amgen's MariTide....
Jun 26
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus,...
Mar 6
William Blair's Andy Hsieh returns to Analyst Thursdays to talk radiopharma buyouts, obesity and more
Andy Hsieh gives his take on the radiopharmaceutical space, Viking’s obesity data, Pyxis Oncology, Cardiff Oncology, Fibrogen.
Mar 21, 2024
William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area
Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into radiopharmaceutical, and discusses AASLD, Seagen, and Icosavax.
Nov 30, 2023
William Blair’s Andy Hsieh joins BiotechTV for Analyst Thursdays
William Blair’s Andy Hsieh discusses recent data from CymaBay, and comments on Madrigal, Viking, Exelixis, POINT, Fusion, and Icosavax.
Sep 28, 2023
.png){kind=logo}
